Mga Batayang Estadistika
| LEI | 54930049FXZMTLW8D496 |
| CIK | 1267565 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Collegium Pharmaceutical, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2025 |
Exhibit 99.2 Q2 2025 Earnings Report August 7, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticip |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2025 |
Exhibit 99.1 Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Pr |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
Exhibit 99.5 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE COLLEGIUM PHARMACEUTICAL, INC. 2025 EQUITY INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: Pursuant to the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan as amended through the date hereof (the “Plan”), Collegium Pharmaceutical, Inc. (the |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
Exhibit 99.4 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE COLLEGIUM PHARMACEUTICAL, INC. 2025 EQUITY INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Vesting Date: Pursuant to the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan as amended through the date hereof (the “Plan”), Collegium Pharmaceutical, Inc. (the “Company”) hereby grants an award of the numbe |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
Form of Incentive Stock Option Award Agreement under the 2025 Equity Inventive Plan (7) Exhibit 99.3 INCENTIVE STOCK OPTION AGREEMENT UNDER THE COLLEGIUM PHARMACEUTICAL, INC. 2025 EQUITY INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [up to 10 years (5 if a 10% owner)] Pursuant to the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan as amended through the |
|
| June 6, 2025 |
Form of Restricted Stock Unit Award Agreement under the 2025 Equity Inventive Plan (7) Exhibit 99.2 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE COLLEGIUM PHARMACEUTICAL, INC. 2025 EQUITY INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan as amended through the date hereof (the “Plan”), Collegium Pharmaceutical, Inc. (the “Company”) hereby grants an award of the number of Restricted |
|
| June 6, 2025 |
Calculation of Registration Fees Calculation of Filing Fee Tables S-8 COLLEGIUM PHARMACEUTICAL, INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. |
|
| May 19, 2025 |
2025 Equity Incentive Plan (6) Exhibit 10.1 COLLEGIUM PHARMACEUTICAL, INC. 2025 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Collegium Pharmaceutical, Inc. (the “Company”) and its Affi |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 8, 2025 |
Exhibit 99.1 Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Genera |
|
| May 8, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the “Company”) and DAVID DIETER (the “Executive”). WHEREAS, the Company desires to employ Executive on at at-will basis, and the Executive wishes to be employed by the Company on at-will basis, on the terms and conditions set forth herein. NOW, THEREFORE, in consider |
|
| May 8, 2025 |
Exhibit 99.2 Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipate |
|
| May 8, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| March 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Org |
|
| March 6, 2025 |
Calculation of Registration Fees Calculation of Filing Fee Tables S-8 COLLEGIUM PHARMACEUTICAL, INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (C |
|
| February 27, 2025 |
Exhibit 99.1 Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered |
|
| February 27, 2025 |
Exhibit 10.20 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the “Company”) and VIKRAM KARNANI (the “Executive”). WHEREAS, the Company desires to employ Executive on at at-will basis, and the Executive wishes to be employed by the Company on at-will basis, on the terms and conditions set forth herein. NOW, THEREFORE, in consi |
|
| February 27, 2025 |
Exhibit 99.2 Q4 and FY2024 Earnings Report February 27, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. |
|
| February 27, 2025 |
Subsidiaries of Collegium Pharmaceutical, Inc. Exhibit 21.1 Subsidiaries of Collegium Pharmaceutical, Inc. Subsidiary Jurisdiction of Incorporation Collegium Securities Corporation Massachusetts Collegium NF, LLC Delaware BioDelivery Sciences International, Inc. Delaware Arius Pharmaceuticals, Inc. Delaware Arius Two, Inc. Delaware Ironshore Therapeutics, Inc. Cayman Islands Ironshore Pharmaceuticals & Development, Inc. Cayman Islands Ironshor |
|
| February 13, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| February 7, 2025 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or O |
|
| January 8, 2025 |
Exhibit 99.1 Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mas |
|
| January 8, 2025 |
Investor Presentation January 2025 | Nasdaq: COLL Healthier people. Stronger communities. Exhibit 99.2 Investor Presentation January 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "antici |
|
| January 8, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Or |
|
| November 14, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On September 3, 2024 (the “Acquisition Date”), Collegium Pharmaceuticals, Inc. (the “Company” or “Collegium”) closed the acquisition (the “Acquisition”) of Ironshore Therapeutics, Inc. (“Ironshore”), pursuant to an Agreement and Plan of Merger (the “Agreement”), dated July 28, 2024. Upon closing of the Acquisiti |
|
| November 14, 2024 |
IRONSHORE THERAPEUTICS, INC. INDEX TO FINANCIAL STATEMENTS Exhibit 99.1 IRONSHORE THERAPEUTICS, INC. INDEX TO FINANCIAL STATEMENTS Page Report of Independent Auditor F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Shareholders’ Deficit F-6 Consolidated Statements of Cash Flows F-7 Notes to Consolidated Financial Statements F-8 Report of Independent Auditors To the Shareholders |
|
| November 14, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction |
|
| November 13, 2024 |
COLL / Collegium Pharmaceutical, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d6sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19459J104 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Chec |
|
| November 13, 2024 |
SC 13G 1 coll.htm PRINCIPAL GLOBAL INVESTORS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 COLLEGIUM PHARMACEUTICAL INC (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 19459J104 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or O |
|
| November 7, 2024 |
Exhibit 99.1 Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed A |
|
| November 7, 2024 |
Exhibit 99.2 Q3’24 Earnings Report November 7, 2024 | Nasdaq: COLL 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," |
|
| November 7, 2024 |
Exhibit 99.3 Collegium Appoints Vikram Karnani as Chief Executive Officer – Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses – STOUGHTON, Mass., November 7, 2024 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious me |
|
| November 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| September 4, 2024 |
Investor Presentation September 2024 | Nasdaq: COLL Exhibit 99.2 Investor Presentation September 2024 | Nasdaq: COLL 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends |
|
| September 4, 2024 |
Exhibit 99.1 Collegium Completes Acquisition of Ironshore Therapeutics – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., September 4 |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or |
|
| August 15, 2024 |
As filed with the Securities and Exchange Commission on August 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| August 15, 2024 |
Calculation of Registration Fees Calculation of Filing Fee Tables S-8 COLLEGIUM PHARMACEUTICAL, INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| August 8, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2024 |
Exhibit 99.2 Q2’24 Earnings Report August 8, 2024 | Nasdaq: COLL 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "m |
|
| August 8, 2024 |
EX-10.1 2 coll-20240630xex10d1.htm EX-10.1 Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AUTHORIZED GENERIC AGREEMENT THIS AUTHORIZED GENERIC AGREEMENT (this “Agreement”), is made effective as of April 26, 2024 (hereinafter the “Effective Date”), b |
|
| August 8, 2024 |
Exhibit 10.2 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (the “Agreement”) is made by and between Joseph Ciaffoni (the “Executive”) and Collegium Pharmaceutical, Inc. (the “Company”). The Executive together with the Company shall be referred to as the “Parties.” WHEREAS, the Parties entered into an Amended & Restated Employment Agreement dated as of December 27, 2020, as |
|
| August 8, 2024 |
Letter Agreement, by and between the Company and Michael Heffernan, dated May 24, 2024. Exhibit 10.3 LETTER AGREEMENT This Letter Agreement (this “Letter Agreement”) is entered into as of May 24, 2024, by and between Collegium Pharmaceutical, Inc. (the “Company”) and Michael Heffernan (“Chairman,” and together with the Company, the “Parties”). RECITALS WHEREAS, Chairman is currently Chairman of the Board of Directors (the “Board”) of the Company; WHEREAS, the Company desires to obtai |
|
| August 8, 2024 |
Exhibit 99.1 Collegium Reports Second Quarter 2024 Financial Results – Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironsh |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 29, 2024 |
Exhibit 10.1 Execution Version CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDED AND RESTATED LOAN AGREEMENT Dated as of July 28, 2024 among COLLEGIUM PHARMACEUTICAL, INC. (as Borrower), THE GUARANTORS FROM TIME TO TIME PARTY HERETO (as additional Cr |
|
| July 29, 2024 |
Exhibit 99.1 Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significant |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Orga |
|
| July 29, 2024 |
Collegium to Acquire Ironshore Therapeutics July 29, 2024 | Nasdaq: COLL Exhibit 99.2 Collegium to Acquire Ironshore Therapeutics July 29, 2024 | Nasdaq: COLL Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects, |
|
| July 29, 2024 |
Exhibit 2.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among COLLEGIUM PHARMACEUTICAL, INC., CARRERA MERGER SUB INC., IRONSHORE THERAPEUTICS INC. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as the Securityholders’ Represe |
|
| June 13, 2024 |
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise Exhibit 99.1 Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise STOUGHTON, Mass., June 13, 2024 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted |
|
| June 13, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Orga |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organi |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2024 |
Exhibit 99.2 Q1’24 Earnings Report May 9, 2024 | Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," |
|
| May 9, 2024 |
Exhibit 99.1 Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board |
|
| April 29, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Org |
|
| April 11, 2024 |
Exhibit 99.1 Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 STOUGHTON, Mass, April 11, 2024 (GLOBE NEWSWIRE) – Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it ha |
|
| April 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Org |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| February 22, 2024 |
Subsidiaries of Collegium Pharmaceutical, Inc. Exhibit 21.1 Subsidiaries of Collegium Pharmaceutical, Inc. Subsidiary Jurisdiction of Incorporation Collegium Securities Corporation Massachusetts Collegium NF, LLC Delaware BioDelivery Sciences International, Inc. Delaware Arius Pharmaceuticals, Inc. Delaware Arius Two, Inc. Delaware |
|
| February 22, 2024 |
Form of Restricted Stock Unit Agreement under the Amended and Restated 2014 Stock Incentive Plan (4) Exhibit 10.4(d) COLLEGIUM PHARMACEUTICAL, INC. AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN Restricted Stock Unit Grant Schedule Grantee’s name:[Name] Grant Date:[Date] Number of Restricted Stock Units granted:[Quantity] Vesting:Subject to the Grantee’s continued service to the Company through the applicable vesting dates, the Restricted Stock Units shall vest in accordance with the schedule bel |
|
| February 22, 2024 |
Exhibit 19 COLLEGIUM PHARMACEUTICAL, INC. INSIDER TRADING POLICY Effective February 8, 2023 (the “Effective Date”) INTRODUCTION This Insider Trading Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”) and provides the standards of the Company on trading of the Company’s securities or securities of other publicly traded c |
|
| February 22, 2024 |
Exhibit 10.14 EXECUTION VERSION CONSENT AND FIRST AMENDMENT TO LOAN AGREEMENT This Consent and First Amendment to Loan Agreement (this “Consent and Amendment”), dated as of January 3, 2023 (the “Effective Date”), is entered into by and among COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation (as “Borrower”), the Guarantors from time to time party thereto, BIOPHARMA CREDIT PLC, a public limited |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. |
|
| February 22, 2024 |
Exhibit 99.2 Q4 and FY 2023 Earnings Report February 22, 2024 | Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "in |
|
| February 22, 2024 |
Exhibit 97 COLLEGIUM PHARMACEUTICAL, INC. CLAWBACK POLICY Effective February 6, 2020 Amended Effective September 22, 2023 (the “Amended Effective Date”) I. PURPOSE The Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”) believes that it is in the best interest of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountab |
|
| February 22, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (C |
|
| February 22, 2024 |
Exhibit 99.1 Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash E |
|
| February 14, 2024 |
COLL / Collegium Pharmaceutical, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Collegium Pharmaceutical, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| February 13, 2024 |
COLL / Collegium Pharmaceutical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0645-collegiumpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Collegium Pharmaceutical Inc Title of Class of Securities: Common Stock CUSIP Number: 19459J104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 12, 2024 |
COLL / Collegium Pharmaceutical, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d5sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check |
|
| January 3, 2024 |
Exhibit 99.1 Collegium Provides 2024 Financial Guidance – Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million – – $150.0 Million Share Repurchase Program Authorized by the Board of Directors – STOUGHTON |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2024 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Or |
|
| January 3, 2024 |
Investor Presentation January 2024 | Nasdaq: COLL Exhibit 99.2 Investor Presentation January 2024 | Nasdaq: COLL Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," " |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or O |
|
| November 7, 2023 |
Exhibit 99.2 Q3’23 Earnings Report November 7, 2023 Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may |
|
| November 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Co |
|
| November 7, 2023 |
Exhibit 99.1 Collegium Reports Third Quarter 2023 Financial Results – Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year – – Received Extension of Nucynta® Regulatory Exclusivity through July 2026 – – Board of Directors Authorized $25. |
|
| August 24, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Or |
|
| August 24, 2023 |
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026 Exhibit 99.1 Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026 STOUGHTON, Mass., Aug. 24, 2023 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Pati |
|
| August 10, 2023 |
Calculation of Registration Fees Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Collegium Pharmaceutical, Inc. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Org |
|
| August 3, 2023 |
Exhibit 10.1 Execution Version THIRD AMENDMENT TO LOAN AGREEMENT This Third Amendment to Loan Agreement (this “Amendment”), dated as of June 23, 2023 (the “Third Amendment Effective Date”), is entered into by and among COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation (as “Borrower”), the Guarantors from time to time party thereto, BIOPHARMA CREDIT PLC, a public limited company incorporated u |
|
| August 3, 2023 |
Exhibit 99.2 Q2’23 Earnings Report August 3, 2023 Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Comm |
|
| August 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2023 |
Exhibit 99.1 Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Authorized $50 Million Accelerated Share Repurchase Program – – Reaffirmed Full Year 2023 Guidance – – Con |
|
| May 19, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 4, 2023 |
Exhibit 99.2 Q1’23 Earnings Report May 4, 2023 Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "c |
|
| May 4, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2023 |
Exhibit 99.1 Collegium Reports First Quarter 2023 Financial Results – Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 4, 2023 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL |
|
| May 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 23, 2023 |
Subsidiaries of Collegium Pharmaceutical, Inc. Exhibit 21.1 Subsidiaries of Collegium Pharmaceutical, Inc. Subsidiary Jurisdiction of Incorporation Collegium Securities Corporation Massachusetts Collegium NF, LLC Delaware BioDelivery Sciences International, Inc. Delaware Arius Pharmaceuticals, Inc. Delaware Arius Two, Inc. Delaware |
|
| February 23, 2023 |
EX-4.7 2 coll-20221231xex4d7.htm EX-4.7 Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S COMMON STOCK References to “the Company,” “Collegium,” “we,” “our” and “us” herein are, unless the context otherwise indicates, only to Collegium Pharmaceutical, Inc. and not to any of its subsidiaries. The following description of our common stock is a summary and does not purport to be complete. It is subject to |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents 04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2023 |
Exhibit 99.1 Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., February 23, 2023 – Collegium Pharmaceutical, Inc. (Nasdaq: COLL), |
|
| February 23, 2023 |
Exhibit 99.2 Q4 and FY 2022 Earnings Report February 23, 2023 Nasdaq: COLL Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "inte |
|
| February 23, 2023 |
Exhibit 10.15 SECOND AMENDMENT TO LOAN AGREEMENT This Second Amendment to Loan Agreement (this “Amendment”), dated as of February 6, 2023 (the “Effective Date”), is entered into by and among COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation (as “Borrower”), the Guarantors from time to time party thereto, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (C |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (state or other jurisdiction of incorporation) (C |
|
| February 13, 2023 |
Exhibit 4.1 EXECUTION VERSION Collegium Pharmaceutical, Inc. and The Bank of New York Mellon Trust Company, N.A. as Trustee INDENTURE Dated as of February 10, 2023 2.875% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 13 Section 1.03. Rules of Construction. 14 Article 2. The Note |
|
| February 13, 2023 |
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering Exhibit 99.1 Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering STOUGHTON, Mass., February 7, 2023—Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant t |
|
| February 10, 2023 |
COLL / Collegium Pharmaceutical Inc / Rubric Capital Management LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 9, 2023 |
COLL / Collegium Pharmaceutical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0621-collegiumpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Collegium Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 19459J104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (state or other jurisdiction of incorporation) (Co |
|
| February 6, 2023 |
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering EX-99.2 3 tm235588d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering STOUGHTON, Mass., February 6, 2023 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a |
|
| February 6, 2023 |
Exhibit 99.1 Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results -Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., February 6, 2023 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmace |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2023 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (state or other jurisdiction of incorporation) (Com |
|
| January 4, 2023 |
Exhibit 99.2 Investor Presentation January 2023 Nasdaq: COLL Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "m |
|
| January 4, 2023 |
Exhibit 99.1 Collegium Provides 2023 Financial Guidance – Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million – – $100 Million Share Repurchase Program Authorized by the Board of Directors – STOUGHTON, |
|
| December 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 (December 21, 2022) Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction |
|
| December 22, 2022 |
Exhibit 99.1 Appeals Court Affirms Validity of Collegium?s Belbuca? Patents ? Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry ? STOUGHTON, Mass., December 22, 2022 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the D |
|
| November 3, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? ? Date of Report (Date of earliest event reported): November 3, 2022 ? ? COLLEGIUM PHARMACEUTICAL, INC. ? (Exact name of registrant as specified in its charter) ? ? ? ? Virginia 001-37372 03-0416362 (State or other ju |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2022 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commiss |
|
| November 3, 2022 |
Exhibit 99.2 November 3, 2022 | Nasdaq: COLL Q3FY22 Earnings Report Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "inten |
|
| November 3, 2022 |
Exhibit 99.1 ? Collegium Reports Third Quarter 2022 Financial Results ? ? Generated Record Net Revenue of $127.0 Million ? ? ? Completed Xtampza? ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning January 2023 ? ? ? Returned $10M in Capital to Shareholders Through Share Repurchases ? ? ? Updated Full Year 2022 Guidance ? ? ? Conference Call Scheduled for |
|
| August 11, 2022 |
Calculation of Registration Fees Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Collegium Pharmaceutical, Inc. |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| August 4, 2022 |
Exhibit 99.2 August 4, 2022 | Nasdaq: COLL Q2FY22 Earnings Report Forward - Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," |
|
| August 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Exhibit 99.1 ? Collegium Reports Second Quarter 2022 Financial Results ? ? Generated Record Net Revenue of $123.5 Million ? ? ? BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million ? ? ? Raises Full Year Adjusted EBITDA Guidance ? ? ? Conference Call Scheduled for Today at 4:30 p.m. ET ? ? STOUGHTON, Mass., August 4, 2022 - Collegium Pharmaceutical, Inc |
|
| August 4, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? ? Date of Report (Date of earliest event reported): August 4, 2022 ? ? COLLEGIUM PHARMACEUTICAL, INC. ? (Exact name of registrant as specified in its charter) ? ? ? ? Virginia 001-37372 03-0416362 (State or other juri |
|
| May 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 13, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On March 22, 2022, Collegium Pharmaceutical, Inc. (the ?Company?) completed the acquisition (the ?Acquisition?) of BioDelivery Sciences International, Inc. (?BDSI?), pursuant to an Agreement and Plan of Merger, dated February 14, 2022, by and among the Company, Bristol Acquisition Company Inc., a Delaware corpor |
|
| May 13, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 23, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of |
|
| May 10, 2022 |
Exhibit 99.1 ? Collegium Reports First Quarter 2022 Financial Results ? - Generated Net Revenue of $83.8 Million - ? - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - ? - Resolved All Opioid-Industry Litigation - ? - Reaffirms 2022 Financial Guidance - ? - Conference Call Scheduled for Today at 4:30 p.m. ET - ? STOUGHTON, Mass., May 10, 2022 - C |
|
| May 10, 2022 |
Exhibit 10.7 ? EMPLOYMENT AGREEMENT ? THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the ?Company?) and THOMAS SMITH (the ?Executive?). ? WHEREAS, the Company desires to employ Executive on at at-will basis, and the Executive wishes to be employed by the Company on at-will basis, on the terms and conditions set forth herein. ? NOW, THEREFORE, in |
|
| May 10, 2022 |
Exhibit 10.5 January 20, 2022 VIA E-MAIL Re: Amendment to Employment Agreement Dear Shirley: Reference is hereby made to the Amended and Restated Employment Agreement effective as of January 1, 2021 (the ?Employment Agreement?) by and between you and Collegium Pharmaceutical, Inc. (the ?Company?). Effective as of the date of this letter, the Company and you agree to amend the Employment Agreement |
|
| May 10, 2022 |
Exhibit 10.6 January 20, 2022 VIA E-MAIL Re: Amendment to Employment Agreement Dear Scott: Reference is hereby made to the Amended and Restated Employment Agreement effective as of January 1, 2021 (the ?Employment Agreement?) by and between you and Collegium Pharmaceutical, Inc. (the ?Company?). Effective as of the date of this letter, the Company and you agree to amend the Employment Agreement as |
|
| May 10, 2022 |
? Exhibit 10.3 January 20, 2022 VIA E-MAIL Re: Amendment to Employment Agreement Dear Joe: Reference is hereby made to the Amended and Restated Employment Agreement dated as of December 27, 2020 (the ?Employment Agreement?) by and between you and Collegium Pharmaceutical, Inc. (the ?Company?). Effective as of the date of this letter, the Company and you agree to amend the Employment Agreement as f |
|
| May 10, 2022 |
Exhibit 99.2 May 10, 2022 | Nasdaq: COLL Q1FY22 Earnings Report Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimat es, " "anticipates," "expects," "plans," "intends |
|
| May 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission |
|
| May 10, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2022 |
Exhibit 10.4 January 20, 2022 VIA E-MAIL Re: Amendment to Employment Agreement Dear Colleen: Reference is hereby made to the Employment Agreement effective as of May 24, 2021 (the ?Employment Agreement?) by and between you and Collegium Pharmaceutical, Inc. (the ?Company?). Effective as of the date of this letter, the Company and you agree to amend the Employment Agreement as follows: 1.Section 5 |
|
| April 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Org |
|
| April 13, 2022 |
Exhibit 99.1 April 2022 | Nasdaq: COLL Corporate Presentation Investor Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plan |
|
| April 6, 2022 |
DEF 14A 1 tmb-20220519xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (a |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Orga |
|
| April 6, 2022 |
DEFA14A 1 tmb-20220406xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only ( |
|
| April 5, 2022 |
Exhibit 99.1 Collegium Provides 2022 Financial Guidance – Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to $250.0 million – STOUGHTON, Mass., April 5, 2022 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, |
|
| April 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Orga |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 (March 22, 2022) Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (State or other jurisdiction of inc |
|
| March 23, 2022 |
Collegium Completes the Acquisition of BDSI Exhibit 99.1 Collegium Completes the Acquisition of BDSI STOUGHTON, Mass., March 22, 2022 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (?Collegium?) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (?BDSI?). ?This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company comm |
|
| March 23, 2022 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit in accordance with Regulation S-K Item 601(a)(6) because it would constitute a clearly unwarranted invasion of personal privacy. [***] indicates that information has been redacted. Execution Version AMENDED AND RESTATED LOAN AGREEMENT Dated as of March 22, 2022 among COLLEGIUM PHARMACEUTICAL, INC. (as Borrower), THE GU |
|
| March 21, 2022 |
SC TO-T/A 1 tm226564d10sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) BRISTOL ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of COLLEGIUM |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) BRISTOL ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of COLLEGIUM PHARMACEUTICAL, INC. (Parent of Offeror) (N |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) BRISTOL ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of COLLEGIUM PHARMACEUTICAL, INC. (Parent of Offeror) (N |
|
| February 24, 2022 |
Exhibit 99.2 February 24, 2022 | Nasdaq: COLL Q4 and FYE 2021 Earnings Report Forward - Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," |
|
| February 24, 2022 |
Subsidiaries of Collegium Pharmaceutical, Inc. Exhibit 21.1 ? Subsidiaries of Collegium Pharmaceutical, Inc. ? Subsidiary Jurisdiction of Incorporation Collegium Securities Corporation Massachusetts Collegium NF, LLC Delaware ? ? ? |
|
| February 24, 2022 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S COMMON STOCK References to ?the Company,? ?Collegium,? ?we,? ?our? and ?us? herein are, unless the context otherwise indicates, only to Collegium Pharmaceutical, Inc. and not to any of its subsidiaries. The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by referen |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents 04 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2022 |
Results of Operations and Financial Condition ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? ? Date of Report (Date of earliest event reported): February 24, 2022 ? ? COLLEGIUM PHARMACEUTICAL, INC. ? (Exact name of registrant as specified in its charter) ? ? ? ? Virginia 001-37372 03-0416362 (State or other j |
|
| February 24, 2022 |
EX-99.1 2 coll-20220224xex99d1.htm EX-99.1 Exhibit 99.1 Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results – BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Sch |
|
| February 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Rule 14d-100) BIODELIVERY SCIENCES INTERNATIONAL, INC. |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) BRISTOL ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of COLLEGIUM PHARMACEUTICAL, INC. (Parent of Offeror) (N |
|
| February 18, 2022 |
Exhibit (d)(5) CONFIDENTIAL February 4, 2022 BioDelivery Sciences International, Inc. |
|
| February 18, 2022 |
Form of Notice of Guaranteed Delivery* ? ?Exhibit (a)(1)(C)? Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of BioDelivery Sciences International, Inc. |
|
| February 18, 2022 |
Exhibit (d)(4) CONFIDENTIAL DISCLOSURE AGREEMENT This Confidential Disclosure Agreement (the ?Agreement?), dated as of December 29, 2021 (the ?Effective Date?), is by and between Collegium Pharmaceutical, Inc. |
|
| February 18, 2022 |
Summary of Newspaper Advertisement, as published in Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| February 18, 2022 |
Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees* ? ?Exhibit (a)(1)(D)? Offer to Purchase All Outstanding Shares of Common Stock of BIODELIVERY SCIENCES INTERNATIONAL, INC. |
|
| February 18, 2022 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9)* ? ?Exhibit (a)(1)(B)? Letter of Transmittal to Tender Shares of Common Stock of BIODELIVERY SCIENCES INTERNATIONAL, INC. |
|
| February 18, 2022 |
Form of Letter to Clients for use by Brokers, Dealers, Banks, Trust Companies and Other Nominees* ? ?Exhibit (a)(1)(E)? Offer to Purchase All Outstanding Shares of Common Stock of BIODELIVERY SCIENCES INTERNATIONAL, INC. |
|
| February 18, 2022 |
EX-FILING FEES 11 tm226564d4ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Rule 14d-100) BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) COLLEGIUM PHARMACEUTICAL, INC. (Names of Filing Persons (Offerors)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of Filing Fee Fees to Be Paid $ 1,196,312,079.36 .0000 |
|
| February 18, 2022 |
? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ? BIODELIVERY SCIENCES INTERNATIONAL, INC. (Name of Subject Company (Issuer)) ? BRISTOL ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of COLLEGIUM PHARMACEUTICAL, INC. (Parent of Offeror) (Names o |
|
| February 18, 2022 |
Offer to Purchase dated February 18, 2022* ? ?Exhibit (a)(1)(A)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of BioDelivery Sciences International, Inc. |
|
| February 18, 2022 |
Exhibit (b)(1) Execution Version STRICTLY CONFIDENTIAL Pharmakon Advisors, L.P. 110 East 59th Street, 33rd Floor New York, NY 10022 February 14, 2022 Collegium Pharmaceutical, Inc. 100 Technology Center Drive, Suite 300 Stoughton, MA 02072 Attention: Colleen Tupper $650 Million Senior Secured Term Loan Facility Commitment Letter Ladies and Gentlemen: Collegium Pharmaceutical, Inc., a Virginia corp |
|
| February 15, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 15, 2022 |
COLL / Collegium Pharmaceutical Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19459J 104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2022 |
COLL / Collegium Pharmaceutical Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Collegium Pharmaceutical, Inc. (Name of Issuer ? as specified in its charter) Common Stock, $0.001 par value (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2022 |
SC 13G/A 1 CamberColl-202113G.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of t |
|
| February 14, 2022 |
COLL / Collegium Pharmaceutical Inc / Rubric Capital Management LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule p |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or |
|
| February 14, 2022 |
EX-10.1 3 tm226564d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FORM OF TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”) is entered into as of February 14, 2022, by and among Collegium Pharmaceutical, Inc., a Virginia corporation (“Parent”), Bristol Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each of the Pers |
|
| February 14, 2022 |
EX-2.1 2 tm226564d2ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: COLLEGIUM PHARMACEUTICAL, INC., BRISTOL ACQUISITION COMPANY INC. and BIODELIVERY SCIENCES INTERNATIONAL, INC. Dated as of February 14, 2022 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE 2 THE OFFER 15 Section 2.1 The Offer 15 Section 2.2 Company Actio |
|
| February 14, 2022 |
Exhibit 10.1 FORM OF TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this ?Agreement?) is entered into as of February 14, 2022, by and among Collegium Pharmaceutical, Inc., a Virginia corporation (?Parent?), Bristol Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Purchaser?), and each of the Persons set forth on Schedule A hereto (each a ? |
|
| February 14, 2022 |
EX-2.1 2 tm226564d1ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: COLLEGIUM PHARMACEUTICAL, INC., BRISTOL ACQUISITION COMPANY INC. and BIODELIVERY SCIENCES INTERNATIONAL, INC. Dated as of February 14, 2022 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE 2 THE OFFER 15 Section 2.1 The Offer 15 Section 2.2 Company Actio |
|
| February 14, 2022 |
Investor Presentation of Collegium Pharmaceutical, Inc. dated February 14, 2022 Exhibit 99.2 Collegium to Acquire BDSI February 14, 2022 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or |
|
| February 14, 2022 |
Press release of Collegium Pharmaceutical, Inc. dated February 14, 2022 Exhibit 99.1 Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA? Provides a Second Growth Driver and ELYXYB? Establishes Foothold in Neurology - - Conference Call Scheduled for |
|
| February 14, 2022 |
Collegium to Acquire BDSI February 14, 2022 EX-99.2 5 tm226564d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Collegium to Acquire BDSI February 14, 2022 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipa |
|
| February 14, 2022 |
Exhibit 99.1 Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA? Provides a Second Growth Driver and ELYXYB? Establishes Foothold in Neurology - - Conference Call Scheduled for |
|
| February 14, 2022 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| February 9, 2022 |
COLL / Collegium Pharmaceutical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Collegium Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 19459J104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| December 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or |
|
| December 28, 2021 |
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation EX-99.1 2 tm2136396d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation STOUGHTON, Mass., December 28, 2021 - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or |
|
| November 4, 2021 |
EX-99.1 2 coll-20211104xex99d1.htm EX-99.1 Exhibit 99.1 Collegium Reports Third Quarter Fiscal 2021 Results - Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program - - Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million - - Full-Year 2021 Guidance Updated - - Conference Call Scheduled for Today at 4:30 p.m. ET - STOUGHTON, Mass., November 4, 2021 - Collegiu |
|
| November 4, 2021 |
Results of Operations and Financial Condition ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? ? Date of Report (Date of earliest event reported): November 4, 2021 ? ? COLLEGIUM PHARMACEUTICAL, INC. ? (Exact name of registrant as specified in its charter) ? ? ? ? Virginia 001-37372 03-0416362 (State or other ju |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 (September 24, 2021) COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdictio |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Or |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 12, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Collegium Pharmaceutical, Inc. |
|
| August 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? Commission f |
|
| August 5, 2021 |
Results of Operations and Financial Condition ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? ? Date of Report (Date of earliest event reported): August 5, 2021 ? ? COLLEGIUM PHARMACEUTICAL, INC. ? (Exact name of registrant as specified in its charter) ? ? ? ? Virginia 001-37372 03-0416362 (State or other juri |
|
| August 5, 2021 |
EX-10.1 2 coll-20210630xex10d1.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the “Company”) and COLLEEN TUPPER (the “Executive”). WHEREAS, the Company desires to employ Executive on at at-will basis, and the Executive wishes to be employed by the Company on at-will basis, on the terms and conditions |
|
| August 5, 2021 |
EX-99.1 2 coll-20210805xex99d1.htm EX-99.1 Exhibit 99.1 Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million – Xtampza® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue Guidance Updated – – Conference Call Scheduled for Today at 4: |
|
| June 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| June 2, 2021 |
Corporate presentation, dated June 2, 2021. EX-99.1 2 tm2118117d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium Pharmaceutical, Inc. Corporate Overview June 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact Name of Registrant as Specified in its Charter) Virginia 001-37372 03-0416362 (State or Other Jurisdiction of Incorporation or Organi |
|
| May 6, 2021 |
Exhibit 99.1 ? Collegium Reports Record Quarterly Revenue of $87.7 Million ? ? Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 ? ? ? Nucynta? Franchise and Adjusted EBITDA 2021 Guidance Range Raised ? ? ? Colleen Tupper Appointed as Next CFO; Paul Brannelly will be Leaving the Company to Pursue Other Opportunities ? ? ? Conference Call Scheduled for To |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 25, 2021 |
Subsidiaries of Collegium Pharmaceutical, Inc. EX-21.1 3 coll-20201231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of Collegium Pharmaceutical, Inc. Subsidiary Jurisdiction of Incorporation Collegium Securities Corporation Massachusetts Collegium NF, LLC Delaware |
|
| February 25, 2021 |
Table of Contents 04 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
EX-99.1 2 coll-20210225xex99d1.htm EX-99.1 Exhibit 99.1 Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million – 2020 First Full-Year of Profitability, Driven by Xtampza® ER Revenue Growth and the Nucynta® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 25, 2021 - Collegium Pharmaceutic |
|
| February 25, 2021 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S COMMON STOCK References to “the Company,” “Collegium,” “we,” “our” and “us” herein are, unless the context otherwise indicates, only to Collegium Pharmaceutical, Inc. and not to any of its subsidiaries. The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by referen |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (state or other jurisdiction of incorporation) (C |
|
| February 16, 2021 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19459J 104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2021 |
JANUS HENDERSON GROUP PLC OWNS 14.7% SC 13G/A 1 coll2102021.txt JANUS HENDERSON GROUP PLC OWNS 14.7% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: Collegium Pharmaceutical, Inc. Title of Class of Securities: Common Stock CUSIP Number: 19459J104 Date of Event Which Requires Filing of this Statement: 12/31/2020 Check the a |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Collegium Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 19459J104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 1, 2021 |
FOR SECTION 13 AND 16 REPORTING OBLIGATIONS coll20a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 19459J104 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Collegium Pharmaceutical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19459J104 (CUSIP Number) December 31, 20 |
|
| January 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 COLLEGIUM PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Virginia 001-37372 03-0416362 (state or other jurisdiction of incorporation) (Com |
|
| January 6, 2021 |
EX-99.1 2 tm211743d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium Provides 2021 Financial Guidance – Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass., January 6, 2021 - Collegium Pha |
